Angiotensin II (Ang II), 1 a major effector peptide of the renin-angiotensin system, is believed to play a critical role in the pathogenesis of cardiovascular remodeling associated with hypertension, heart failure, and atherosclerosis (1). Ang II binds to at least two types of receptor with high affinity, designated AT 1 and AT 2 receptors (2). We and others (3, 4) previously cloned the AT 1 receptor that belongs to the superfamily of heterotrimeric G protein-coupled receptors (GPCRs). The AT 1 receptor activates phospholipase C  through the G q protein to generate inositol trisphosphate (IP 3 ) and diacylglycerol, which in turn releases calcium from intracellular stores and activates protein kinase C, respectively (5, 6). At present, the AT 1 receptor is thought to mediate almost all the known physiological and pathological effects of Ang II on the target cells such as vascular smooth muscle cells (VSMC) (7-9), cardiomyocytes (5), cardiac fibroblasts (10), and renal mesangial cells (11).Since the AT 1 receptor is a key mediator in the biologic mechanisms of the renin-angiotensin system, there has been considerable interest in defining its signaling pathways that mediate the cardiovascular physiology. In cultured VSMC, Ang II activates extracellular signal-regulated kinase (ERK), which is an obligatory step for the Ang II-induced cellular hypertrophy of VSMC (12). We and others recently reported that Ang II-induced calcium-dependent transactivation of the epidermal growth factor (EGF) receptor plays a predominant role in the ERK activation by Ang II in VSMC (13) and in cardiac fibroblasts (14). Src family kinase and Pyk2, a recently identified calcium-sensitive tyrosine kinase, seem to be involved in the EGF receptor transactivation by Ang II in VSMC (15).Recent studies of the  2 -adrenergic receptor suggest that agonist-promoted receptor internalization plays an important role in ERK activation (16). In Rat 1a fibroblasts, the GPCRmediated activation of ERK is sensitive to four mechanistically distinct inhibitors of clathrin-mediated endocytosis, concanavalin A (ConA), hypertonic medium, depletion of intracellular potassium, and monodansylcadaverine (17). In addition, expression of dominant inhibitory mutants of -arrestin1 or dynamin, which attenuate agonist-induced receptor internalization, inhibits  2 -adrenergic receptor-mediated ERK activation (16, 18). Since GPCRs appear to internalize through a clathrin-mediated process and AT 1 receptor internalization is blocked by ConA (19), we performed studies to examine the possible requirement of AT 1 receptor internalization for the receptor signaling using the receptor internalization blocker ConA and the receptor mutants with impaired internalization. We obtained evidence that AT 1 receptor internalization is not required for the early signaling events and the downstream ERK activation by the receptor in VSMC. Furthermore, we found that ConA blocked Ang II-induced activation of ERK through a distinct mechanism, the ConA-mediated proteolysis of the EGF recept...